FGF19 and atrial fibrillation: In summary, the present study on the suppressed GM–BA–FGF19 axis in patients with AF provided valuable resources and biological insights to facilitate future bacterial engineering and prebiotics‐based intervention medicine and enhance our understanding of the crosstalk between GM and cardiometabolic health.